Mapping the Certolizumab Pegol Epitope on Tumor Necrosis Factor and Comparison With Infliximab, Adalimumab, and Etanercept

被引：0
|
作者：
Henry, Alistair
Gong, Hai Ping
Nesbitt, Andrew N.
机构：
来源：
GASTROENTEROLOGY | 2011年 / 140卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：S630 / S630
页数：1
相关论文
共 50 条
  • [21] Comparison of the penetration of certolizumab pegol and adalimumab in inflamed and noninflamed mouse tissue
    Nesbitt, Andrew M.
    Palframan, Roger T.
    Vugler, Alex D.
    Moore, Adrian R.
    Baker, Mark B.
    Foulkes, Roland
    Gozzard, Neil
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2007, 102 : S472 - S472
  • [22] Profiles of Switches in Patient with Ankylosing Spondylitis: Comparing Adalimumab, Etanercept, Infliximab, Golimumab and Certolizumab
    Choquette, Denis
    Bessette, Louis
    Raynauld, Jean-Pierre
    Pelletier, Jean-Pierre
    Haraoui, Boulos
    Villeneuve, Edith
    Massicotte, Frederic
    Remillard, Marie-Anais
    Sauvageau, Diane
    Coupal, Louis
    JOURNAL OF RHEUMATOLOGY, 2015, 42 (07) : 1345 - 1345
  • [23] Clinical Response to Infliximab after Secondary Failure with Adalimumab or Certolizumab Pegol in Crohn's Disease
    Trivella, Juan
    Yarur, Andres
    Moroney, James
    Deshpande, Amar
    Abreu, Maria
    Sussman, Daniel
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2013, 108 : S560 - S561
  • [24] Estimation of induction and maintenance costs of infliximab, adalimumab and certolizumab pegol in managing Crohn's disease
    Feagan, Brian
    Tan, Seng
    Malone, Daniel
    Hinojosa, Joaquin
    Brown, Martin
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2008, 103 : S392 - S392
  • [25] A COMPARISON OF DRUG SURVIVAL TIMES FOR INFLIXIMAB, ADALIMUMAB AND ETANERCEPT
    Pocock, Joanna M.
    Albreshni, Samir
    Slack, Ruth
    Polydoropoulou, Varvara
    O'Reilly, David
    Oestoer, Andrew J.
    RHEUMATOLOGY, 2009, 48 : I69 - I69
  • [26] Molecular Basis for the Neutralization of Tumor Necrosis Factor α by Certolizumab Pegol in the Treatment of Inflammatory Autoimmune Diseases
    Lee, Jee Un
    Shin, Woori
    Son, Ji Young
    Yoo, Ki-Young
    Heo, Yong-Seok
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2017, 18 (01)
  • [27] Estimation of induction and maintenance costs of Infliximab, Adalimumab and Certolizumab Pegol in managing Crohn's Disease
    Feagan, B.
    Tan, S.
    Malone, D.
    Hinojosa, J.
    Brown, M.
    INFLAMMATORY BOWEL DISEASES, 2008, 14 (12) : S33 - S33
  • [28] Stoichiometry of binding to and complex formation with tnf by certolizumab pegol, adalimumab, and infliximab and the biologic effects of these complexes
    Henry, A.
    Kennedy, J.
    Fossati, G.
    Nesbitt, A.
    ANNALS OF THE RHEUMATIC DISEASES, 2007, 66 : 82 - 82
  • [29] Assessment of the affinity for soluble TNF and the neutralising potency against soluble and membrane tnf of the anti-tnf agents certolizumab pegol, adalimumab, etanercept and infliximab
    Gramlick, A.
    Fossati, G.
    Henry, A. J.
    Stephens, P. E.
    Nesbitt, A. M.
    ANNALS OF THE RHEUMATIC DISEASES, 2006, 65 : 456 - 456
  • [30] Binding activities of infliximab and etanercept to transmembrane tumor necrosis factor-α -: Reply
    Van den Brande, JHM
    Bratt, H
    Van Deventer, SJH
    Peppelenbosch, MP
    GASTROENTEROLOGY, 2004, 126 (03) : 935 - 936
12345